TSHA
NASDAQ HealthcareTaysha Gene Therapies, Inc. - Common Stock
Biotechnology
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
๐ Market Data
| Price | $5.97 |
|---|---|
| Volume | 3,549,193 |
| Market Cap | 1.72B |
| Beta | 1.160 |
| RSI (14-Day) | 46.5 |
| 200-Day MA | $5.18 |
| 50-Day MA | $6.12 |
| 52-Week High | $7.30 |
| 52-Week Low | $2.34 |
| Forward P/E | -13.72 |
| Price / Book | 8.09 |
๐ฏ Investment Strategy Scores
TSHA scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Moon Shot (71/100) โ this strategy High growth potential (high beta + oversold).
Lowest fit among scored strategies: ๐ฐ Dividend Daddy (22/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find TSHA in your text
Paste any article, transcript, or post โ the tool will extract TSHA and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-07-16.